Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1

Cellular entry of nanoparticles via serum sensitive clathrin-mediated endocytosis, and plasma membrane permeabilization [Corrigendum]

Authors Smith PJ, Giroud M, Wiggins HL, Gower F, Thorley JA, Stolpe B, Mazzolini J, Dyson RJ, Rappoport JZ

Received 6 May 2015

Accepted for publication 6 May 2015

Published 16 June 2015 Volume 2015:10(1) Pages 3987—3988

DOI https://doi.org/10.2147/IJN.S88056

Corrigendum
 
Smith PJ, Giroud M, Wiggins HL, et al. Int J Nanomedicine. 2012;7:2045–2055.

Page 2054, Figure 11, the text “Average no of NPs in lumen: Nf =2.1×10-3” should read “Average no of NPs in lumen:
Nf =2.1×10-2”.
 
Page 2054, Figure 11, the figure legend “Figure 11 A series of calculations to estimate the number of nanoparticles that could enter a vesicle under the incubation conditions described in materials and methods. It is estimated that nanoparticles are nearly 25,000 times more likely to enter cells when they are bound to the membrane than in the fluid phase.” should read “Figure 11 A series of calculations to estimate the number of nanoparticles that could enter a vesicle under the incubation conditions described in materials and methods. It is estimated that nanoparticles are nearly 2,500 times more likely to enter cells when they are bound to the membrane than in the fluid phase.”
 
Page 2054, first column, line 13, the sentence “Even though the latter might be an overestimation, the current analyses suggest that under these conditions nanoparticles are nearly 25,000 times more likely to enter cells bound to the inner membrane of a vesicle than through the fluid phase.” should read “Even though the latter might be an overestimation, the current analyses suggest that under these conditions nanoparticles are nearly 2,500 times more likely to enter cells bound to the inner membrane of a vesicle than through the fluid phase”.

Read the original article



Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Cellular entry of nanoparticles via serum sensitive clathrin-mediated endocytosis, and plasma membrane permeabilization

Smith PJ, Giroud M, Wiggins HL, Gower F, Thorley JA, Stolpe B, Mazzolini J, Dyson RJ, Rappoport JZ

International Journal of Nanomedicine 2012, 7:2045-2055

Published Date: 24 April 2012

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity

Li H, Wu C, Chen T, Zhang G, Zhao H, Ke C, Xu Z,

International Journal of Nanomedicine 2015, 10:4783-4796

Published Date: 30 July 2015

Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles

Naeem M, Cao J, Choi M, Kim WS, Moon HR, Lee BL, Kim MS, Jung Y, Yoo JW

International Journal of Nanomedicine 2015, 10:4565-4580

Published Date: 16 July 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010